PBE holdings
Invesco Biotechnology & Genome ETF
Positions
33 stored of 33 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Invesco Private Prime Fund | Not reported | Not reported | 12.890% | $36.3M | Short-term investment vehicles (cash funds) | Private fund | United States | USD |
| 2 | Regeneron Pharmaceuticals, Inc. | US75886F1075 | 75886F107 | 5.473% | $15.4M | Equity (common) | Corporate | United States | USD |
| 3 | Amgen Inc. | US0311621009 | 031162100 | 5.222% | $14.7M | Equity (common) | Corporate | United States | USD |
| 4 | CareDx, Inc. | US14167L1035 | 14167L103 | 5.041% | $14.2M | Equity (common) | Corporate | United States | USD |
| 5 | Vertex Pharmaceuticals Inc. | US92532F1003 | 92532F100 | 4.985% | $14.1M | Equity (common) | Corporate | United States | USD |
| 6 | Invesco Private Government Fund | Not reported | Not reported | 4.966% | $14.0M | Short-term investment vehicles (cash funds) | Private fund | United States | USD |
| 7 | Royalty Pharma PLC Royalty Pharma PLC, Class A | GB00BMVP7Y09 | G7709Q104 | 4.941% | $13.9M | Equity (common) | Corporate | United Kingdom | USD |
| 8 | Biogen Inc. | US09062X1037 | 09062X103 | 4.787% | $13.5M | Equity (common) | Corporate | United States | USD |
| 9 | Gilead Sciences, Inc. | US3755581036 | 375558103 | 4.435% | $12.5M | Equity (common) | Corporate | United States | USD |
| 10 | United Therapeutics Corp. | US91307C1027 | 91307C102 | 4.076% | $11.5M | Equity (common) | Corporate | United States | USD |
| 11 | Bio-Techne Corp. | US09073M1045 | 09073M104 | 3.734% | $10.5M | Equity (common) | Corporate | United States | USD |
| 12 | Illumina, Inc. | US4523271090 | 452327109 | 3.509% | $9.9M | Equity (common) | Corporate | United States | USD |
| 13 | Protagonist Therapeutics, Inc. | US74366E1029 | 74366E102 | 3.395% | $9.6M | Equity (common) | Corporate | United States | USD |
| 14 | Vericel Corp. | US92346J1088 | 92346J108 | 3.265% | $9.2M | Equity (common) | Corporate | United States | USD |
| 15 | Alnylam Pharmaceuticals, Inc. | US02043Q1076 | 02043Q107 | 3.168% | $8.9M | Equity (common) | Corporate | United States | USD |
| 16 | Incyte Corp. | US45337C1027 | 45337C102 | 3.058% | $8.6M | Equity (common) | Corporate | United States | USD |
| 17 | Repligen Corp. | US7599161095 | 759916109 | 3.041% | $8.6M | Equity (common) | Corporate | United States | USD |
| 18 | Acadia Pharmaceuticals Inc. | US0042251084 | 004225108 | 3.023% | $8.5M | Equity (common) | Corporate | United States | USD |
| 19 | Halozyme Therapeutics, Inc. | US40637H1095 | 40637H109 | 2.984% | $8.4M | Equity (common) | Corporate | United States | USD |
| 20 | Qiagen N.V. | NL0015002SN0 | N72482156 | 2.894% | $8.2M | Equity (common) | Corporate | Netherlands | USD |
| 21 | BioMarin Pharmaceutical Inc. | US09061G1013 | 09061G101 | 2.820% | $8.0M | Equity (common) | Corporate | United States | USD |
| 22 | Neurocrine Biosciences, Inc. | US64125C1099 | 64125C109 | 2.661% | $7.5M | Equity (common) | Corporate | United States | USD |
| 23 | Exelixis, Inc. | US30161Q1040 | 30161Q104 | 2.636% | $7.4M | Equity (common) | Corporate | United States | USD |
| 24 | BioCryst Pharmaceuticals, Inc. | US09058V1035 | 09058V103 | 2.634% | $7.4M | Equity (common) | Corporate | United States | USD |
| 25 | Veracyte, Inc. | US92337F1075 | 92337F107 | 2.603% | $7.3M | Equity (common) | Corporate | United States | USD |
| 26 | Collegium Pharmaceutical, Inc. | US19459J1043 | 19459J104 | 2.603% | $7.3M | Equity (common) | Corporate | United States | USD |
| 27 | Omeros Corp. | US6821431029 | 682143102 | 2.525% | $7.1M | Equity (common) | Corporate | United States | USD |
| 28 | PTC Therapeutics, Inc. | US69366J2006 | 69366J200 | 2.498% | $7.0M | Equity (common) | Corporate | United States | USD |
| 29 | AnaptysBio, Inc. | US0327241065 | 032724106 | 2.295% | $6.5M | Equity (common) | Corporate | United States | USD |
| 30 | Sarepta Therapeutics, Inc. | US8036071004 | 803607100 | 2.215% | $6.2M | Equity (common) | Corporate | United States | USD |
| 31 | Ardelyx, Inc. | US0396971071 | 039697107 | 1.968% | $5.5M | Equity (common) | Corporate | United States | USD |
| 32 | Legend Biotech Corp. Legend Biotech Corp., ADR | US52490G1022 | 52490G102 | 1.561% | $4.4M | Equity (common) | Corporate | Cayman Islands | USD |
| 33 | Invesco Government & Agency Portfolio Invesco Government & Agency Portfolio, Institutional Class | US8252528851 | 825252885 | 0.077% | $216K | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |